GLR-2007 is under clinical development by Gan & Lee Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GLR-2007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GLR-2007 overview

GLR-2007 is under development for the treatment of advanced solid tumors, glioblastoma multiforme, malignant glioma, high-grade glioma, medulloblastoma, primary central lymphoma, ventricular ducts Meningioma, germ cell tumor, recurrent malignant meningioma (WHO grade II-III), breast cancer, metastatic breast cancer, glioma and non small cell lung cancer as a third line therapy. It is administered by oral route.

Gan & Lee Pharmaceuticals overview

Gan & Lee Pharmaceuticals (Gan & Lee), formerly Beijing Gan & Lee Biotechnology, is a biopharmaceutical company. It carries out the research and development, production and sales of recombinant insulin analog APIs and injections. The company product portfolio includes long-acting insulin glargine injection, fast-acting insulin lispro injection, insulin aspart injection, lispro mixed injection, premixed protamine human insulin mixed injection. Gan & Lee also offers cover related medical devices, including reusable insulin injection pens and disposable pen needle. The company utilizes its patented intramolecular chaperone technology for production of recombinant human insulin and insulin analogs. Gan & Lee is headquartered in Beijing, China.

For a complete picture of GLR-2007’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.